etanercept treatment at a dose of 50 mg twice weekly respectively. 6,7 Our results are consistent with placebo-controlled trials regarding long-term efficacy ( ‡6 months of treatment), but have lower values for short-term efficacy (week 12), perhaps because in daily practice difficult-to-treat cases and patients with several comorbidities are candidates for biological therapies in contrast with trials. References 1 Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88(5): 1242-1247. 2 Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726. 3 Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 2007; 17(6): 546-547. 4 Driessen RJB, Boezeman JB, Van de Kerkhof PCM, De Jong EM. Threeyear registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675. 5 Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. 6 Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312. 7 Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue and depression in psoriasis: double-blind placebo controlled randomized phase III trial.